| Ytd | 84.85% | |
| 1y | 78.41% |
| Open | 52.33 | Prev Close | 52.40 | Low | 50.96 | High | 52.63 | Mkt Cap | 8.62B |
| Vol | 1.64M | Avg Vol | 2.30M | EPS | 0.90 | P/E | 57.47 | Forward P/E | 33.23 |
| Beta | 0.33 | Short Ratio | 9.15 | Inst. Own | 110.81% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-28 | 50-d Avg | 40.59 | 200-d Avg | 33.09 | 1yr Est | 49.44 |
ALKS News
Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and raise
Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrad
B of A Securities analyst Jason Gerberry downgrades Alkermes (NASDAQ:ALKS) from Neutral to Underp
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs
Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target
TD Cowen analyst Joseph Thome maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price ta
Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t
Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target
— First Large Phase 2 Study of an Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and
Company seeks to advance national expansion through innovative financing model; Founder personally i
Alkermes plc (NASDAQ:ALKS) today announced that alixorexton, a novel, investigational, oral, selecti
RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises
— 26 Abstracts Accepted Demonstrate Alkermes' Commitment to Advancing Understanding and Treatmen